The role of exome data reanalysis in clarifying STXBP3 associated inflammatory bowel disease and hearing loss

. 2025 ; 13 () : goaf053. [epub] 20250616

Status PubMed-not-MEDLINE Jazyk angličtina Země Velká Británie, Anglie Médium electronic-ecollection

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/pmid40575033

Zobrazit více v PubMed

Nameirakpam J, Rikhi R, Rawat SS  et al.  Genetics on early onset inflammatory bowel disease: an update. Genes Dis  2020;7:93–106. PubMed PMC

Ouahed J, Kelsen JR, Spessott WA  et al.  Variants in PubMed PMC

Levine A, Griffiths A, Markowitz J  et al.  Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis  2011;17:1314–21. PubMed

Daperno M, D'Haens G, Van Assche G  et al.  Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc  2004;60:505–12. PubMed

Turner D, Griffiths AM, Walters TD  et al.  Mathematical weighting of the pediatric Crohn’s disease activity index (PCDAI) and comparison with its other short versions. Inflamm Bowel Dis  2012;18:55–62. PubMed

Sturm M, Admard J, Schütz L  et al. IMGAG/megSAP (Version 2024_09). Zenodo, 2024. 10.5281/zenodo.13744183 DOI

Richards S, Aziz N, Bale S  et al. ; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med  2015;17:405–24. PubMed PMC

Yarur AJ, Rubin DT.  Therapeutic drug monitoring of anti-tumor necrosis factoragents in patients with inflammatory bowel diseases. Inflamm Bowel Dis  2015;21:1709–18. PubMed

Rosario M, Dirks NL, Milch C  et al.  A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab. Clin Pharmacokinet  2017;56:1287–301. PubMed PMC

Colombel J-F, Ungaro RC, Sands BE  et al.  Vedolizumab, adalimumab, and methotrexate combination therapy in Crohn’s disease (EXPLORER). Clin Gastroenterol Hepatol  2024;22:1487–96.e12. PubMed

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...